NCT01489345View on ClinicalTrials.gov

Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2012

Conditions

Healthy

Interventions

DRUG

ONO-2952

30 mg to 100 mg QD at a multiple dose, and 21 days duration

DRUG

ONO-2952 Matching Placebo

30 mg to 100 mg QD at a multiple dose, and 21 days duration

Trial Locations (1)

78744

Austin Clinical Site, Austin

Sponsors

Lead Sponsor

Ono Pharma USA Inc

All Listed Sponsors

lead

Ono Pharma USA Inc

INDUSTRY

NCT01489345 - Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter